Abiopharma

🔍 Sloan Sheldon (Executive)

Company: Spyre Therapeutics, Inc. (SYRE)

Report Date: 2026-05-01

Detailed Transactions and Holdings:

• Acquired 78,333 shares of Common Stock at $27.46 per share (Direct)
  Date: 2026-05-01 | Code: M | equity_swap_involved: 0 | shares_owned_after: 78,333.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 21,306 shares of Common Stock at $69.53 per share (Direct)
  Date: 2026-05-01 | Code: S | equity_swap_involved: 0 | shares_owned_after: 57,027.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 19,656 shares of Common Stock at $70.61 per share (Direct)
  Date: 2026-05-01 | Code: S | equity_swap_involved: 0 | shares_owned_after: 37,371.00 | transaction_form_type: 4 | Footnotes: F1, F3
• Sold 8,777 shares of Common Stock at $71.56 per share (Direct)
  Date: 2026-05-01 | Code: S | equity_swap_involved: 0 | shares_owned_after: 28,594.00 | transaction_form_type: 4 | Footnotes: F1, F4
• Sold 12,777 shares of Common Stock at $72.94 per share (Direct)
  Date: 2026-05-01 | Code: S | equity_swap_involved: 0 | shares_owned_after: 15,817.00 | transaction_form_type: 4 | Footnotes: F1, F5
• Sold 10,358 shares of Common Stock at $73.74 per share (Direct)
  Date: 2026-05-01 | Code: S | equity_swap_involved: 0 | shares_owned_after: 5,459.00 | transaction_form_type: 4 | Footnotes: F1, F6
• Sold 5,059 shares of Common Stock at $74.6 per share (Direct)
  Date: 2026-05-01 | Code: S | equity_swap_involved: 0 | shares_owned_after: 400.00 | transaction_form_type: 4 | Footnotes: F1, F7
• Sold 400 shares of Common Stock at $75.37 per share (Direct)
  Date: 2026-05-01 | Code: S | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F1
• Sold 78,333 shares of Stock Option (Right to Buy) at $27.46 per share (Derivative)
  Date: 2026-05-01 | Code: M | Expires: 2034-10-01 | equity_swap_involved: 0 | shares_owned_after: 321,667.00 | transaction_form_type: 4 | Footnotes: F1, F8

Footnotes:

• F1: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025.
• F2: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $69.21 to $70.16, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range.
• F3: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $70.21 to $71.20, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
• F4: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $71.21 to $72.19, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
• F5: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $72.21 to $73.20, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
• F6: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $73.21 to $74.20, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
• F7: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $74.21 to $74.96, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
• F8: This option represents the right to purchase 400,000 shares of the Issuer's common stock, one quarter of vested and became exercisable on October 1, 2025, with the remaining three quarters vesting in monthly installments over the following three years, subject to the Reporting Person's continued employment with the Issuer.